HC Wainwright Reiterates Buy Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP)

Armata Pharmaceuticals (NYSEAMERICAN:ARMP)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 122.22% from the stock’s current price.

Armata Pharmaceuticals Trading Up 5.0 %

Armata Pharmaceuticals stock opened at $3.15 on Thursday. The stock has a market capitalization of $113.87 million, a P/E ratio of -1.39 and a beta of 0.75. Armata Pharmaceuticals has a 12-month low of $1.07 and a 12-month high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Tuesday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.41). The business had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $1.20 million. As a group, equities analysts predict that Armata Pharmaceuticals will post -1.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Armata Pharmaceuticals

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC grew its stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,777 shares of the company’s stock after purchasing an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned about 0.09% of Armata Pharmaceuticals worth $137,000 at the end of the most recent quarter. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.